Origin of replication-glutamine synthetase gene expression vector and application thereof
The expression vector with a cryptic TATA box and hCMV enhancer in CHO cells addresses integration and MSX reliance issues, enhancing stable protein production efficiency and reducing vector complexity.
Patent Information
- Application Number
- PCT/US2026/028162
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-01-02
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional GS expression vectors for CHO cells face challenges in achieving stable, elevated product titers due to suboptimal integration into actively transcribed loci and the need for high concentrations of methionine sulfoximine (MSX) for selection, which diverts cellular resources from protein production.
An expression vector with a cryptic TATA box and/or cryptic transcription start site operably linked to a glutamine synthetase gene, combined with a transcription control element comprising a human cytomegalovirus enhancer sequence and a mammalian endogenous promoter, enhances control over glutamine synthetase expression, allowing for stable integration and reduced reliance on MSX.
The vector provides increased control over glutamine synthetase expression, enabling stable, elevated protein production with reduced vector size and improved transfection efficiency, and eliminates the need for MSX, maintaining long-term expression stability and product titer.
Smart Images

Figure US2026028162_19112026_PF_FP_ABST
Abstract
Description
Attorney Docket No. 0132-0386W01ORI-GS EXPRESSION VECTOR AND APPLICATION THEREOF REFERENCE TO ELECTRONIC SEQUENCE LISTING
[0001] The application contains a Sequence Listing which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on May 13, 2026, is named “0132-0386W01_SL.xml” and is 44,903 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety.FIELD OF THE INVENTION
[0002] The present disclosure relates to an expression vector for selecting cells and achieving enhanced and controlled expression of recombinant proteins in CHO cells. In some embodiments, the present disclosure provides an expression vector comprising: (a) a bacterial origin of replication (Ori) comprising a cryptic TATA box and / or a cryptic transcription start site, the Ori operably linked to a glutamine synthetase gene; and (b) a transcription control element comprising: (i) an enhancer nucleotide sequence comprising about 300 to about 410 nucleotides of a human cytomegalovirus (hCMV) sequence; and (ii) a mammalian endogenous promoter, wherein the transcription control element is operably linked to a gene of interest (GO I).BACKGROUND
[0003] The glutamine synthetase (GS) knockout-Chinese Hamster Ovary (CHO) expression system is a leading mammalian system for biopharmaceutical production. Conventional GS expression vectors are based on two different promoters: a strong promoter (e.g. CMV) for product gene(s) and a weaker promoter (e.g. SV40) for the GS gene, and further requires a bacterial origin of replication (Ori) for replicating the plasmid (see, e.g., the exemplary schematic shown in FIG. 1 A). While the weaker promoter allows effective stable cell selection, it can be suboptimal, e.g., when systems have preferential integration into actively transcribed loci (i.e., increase in both product gene and GS gene expression). Various studies have shown enhanced cell productivity at higher selection stringency, achieved by increasing the concentration of the selection reagent methionine sulfoximine (MSX). Other strategies that have been explored for increased selection stringency are: (i) very weak promoters to attenuate GS gene expression, (ii) mutation of GS amino acids for reduced GS activity, and (iii) rapid degradation of GS mRNA or GS enzyme. In most cases, the above GS attenuation strategies also lead to significant increases in stable pool recovery time. Additionally,Attorney Docket No. 0132-0386W01strategies (ii) and (iii) are less desirable as the host cells still have to produce large amounts of GS mRNA / protein, thus titrating away cellular resources that otherwise can be utilized for protein of interest production. An improved GS selection system is needed to drive and maintain stable, elevated product titers in the GS-CHO system.SUMMARY OF THE INVENTION
[0004] The present disclosure provides an expression vector for selecting cells and achieving enhanced and controlled expression of recombinant proteins in CHO cells. In some embodiments, the present disclosure provides an expression vector comprising: (a) a bacterial origin of replication (Ori) comprising a cryptic TATA box and / or a cryptic transcription start site, the Ori operably linked to a glutamine synthetase gene; and (b) a transcription control element comprising: (i) an enhancer nucleotide sequence comprising about 300 to about 410 nucleotides of a human cytomegalovirus (hCMV) sequence; and (ii) a mammalian endogenous promoter, wherein the transcription control element is operably linked to a gene of interest (GO I).
[0005] In some embodiments, the transcription control element provides increased control of glutamine synthetase expression. In some embodiments, the transcription control element comprises the enhancer nucleotide sequence comprising about 400 to about 410 nucleotides of the human cytomegalovirus (hCMV) sequence and a human EFla promoter.
[0006] In some embodiments, the Ori comprises any one of SEQ ID NO: 17-22. In some embodiments, the transcription control element comprises an enhancer nucleotide sequence of any one of SEQ ID NO:7-9. In some embodiments, the transcription control element comprises a mammalian endogenous promoter of any one of SEQ ID NO: 1-6. In some embodiments, the transcription control element comprises any one of SEQ ID NO: 10-16.
[0007] In some embodiments, the expression vector further comprises an AU-rich element. In some embodiments, the AU-rich element comprises SEQ ID NO: 26. In some embodiments, the expression vector comprises 1 to 11 copies of the AU-rich element. In some embodiments, the expression vector further comprises a selectable marker for bacterial expression. In some embodiments, the selectable marker is an ampicillin resistance gene, a kanamycin resistance gene, a chloramphenicol resistance gene, or tetracycline resistance gene, or combinations thereof.
[0008] In some embodiments, the GOI encodes a polypeptide of interest. In some embodiments, the polypeptide of interest is an antibody or antigen-binding fragment thereof,Attorney Docket No. 0132-0386W01a fusion protein, an immunoglobulin, an engineered protein, a protein fragment or an enzyme. In some embodiments, the polypeptide of interest is monospecific antibody, a bispecific antibody, or a multi-specific antibody, or antigen-binding fragments thereof.
[0009] In some embodiments, the vector comprises about 345 fewer nucleotides and / or one fewer genetic element as compared to an expression vector in which an Ori is not operably linked to a glutamine synthase gene.
[0010] In a further embodiment, the present disclosure provides a stably integrated cell comprising the expression vector described herein. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a CHO cell or CHO-derived cell. In some embodiments, the CHO cell is CHOK1SV. In some embodiments, the CHO cell comprises a deletion of an endogenous glutamine synthetase gene. In some embodiments, the present disclosure provides a method of expressing a polypeptide of interest in a host cell, comprising culturing the stability integrated cell as described herein under suitable conditions to produce a polypeptide of interest. In some embodiments, the method produces less than about 15% change in titer of a stable pool after 30 days in culture as compared to a method utilizing an expression vector in which an Ori is not operably linked to a glutamine synthetase gene.[OH] In a further embodiment, the present disclosure provides a method of selecting a cell expressing a gene of interest (GOI), comprising:a. transfecting into a cell that lacks glutamine synthetase, an expression vector comprising:i. a bacterial origin of replication (Ori) comprising a cryptic TATA box and / or a cryptic transcription start site, the Ori operably linked to glutamine synthetase; andii. a transcription control element comprising:1. an enhancer nucleotide sequence comprising about 400 to about 410 nucleotides of a human cytomegalovirus (hCMV) sequence; and 2. a mammalian endogenous promoter,wherein the transcription control element is operably linked to a GOI; and b. culturing the transfected cells under conditions that select for cells which stably integrate the vector.
[0012] In some embodiments, the method provides increased control of expression of the glutamine synthetase gene as compared to a method utilizing an expression vector comprisingAttorney Docket No. 0132-0386W01a viral promoter instead of the transcriptional control element. In some embodiments, the mammalian endogenous promoter is the hEFla promoter.
[0013] In some embodiments, the cells which stably integrate the vector are selected by culturing the transfected cells without glutamine. In some embodiments, methionine sulfoximine (MSX) is not used in the culturing of the transfected cells.
[0014] In some embodiments, the transfected cells are mammalian cells. In some embodiments, the transfected cells are CHO cells or CHO-derived cells. In some embodiments, the transfected cells are CHOK1SV cells. In some embodiments, the CHO cells comprise a deletion of an endogenous glutamine synthetase gene.
[0015] In some embodiments, the GOI encodes a polypeptide of interest. In some embodiments, the polypeptide of interest is an antibody, or antigen-binding fragment thereof, a fusion protein, an immunoglobulin, an engineered protein, a protein fragment or an enzyme. In some embodiments, the polypeptide of interest is monospecific antibody, a bispecific antibody, or a multi-specific antibody, or antigen-binding fragments thereof. In some embodiments, the present disclosure provides a method of producing a polypeptide of interest in a host cell comprising selecting cells with the method as described herein and isolating the polypeptide of interest. In some embodiments, the method produces less than about 15% change in titer of a stable pool after 30 days in culture as compared to a method utilizing an expression vector in which an Ori is not operably linked to a glutamine synthetase gene. In some embodiments, the expression vector comprises about 345 fewer nucleotides and / or one fewer genetic element as compared to an expression vector in which an Ori is not operably linked to a glutamine synthetase gene.BRIEF DESCRIPTION OF THE FIGURES
[0016] The following drawings form part of the present specification and are included to further demonstrate exemplary embodiments of certain aspects of the present invention.
[0017] FIGS. 1A-1C show schematics of a conventional GS expression vector (FIG. 1A), the Ori-GS expression (FIG. IB), and the Ori-GS-AU expression vector (FIG. 1C).
[0018] FIGS. 2A-2D show viable cell concentration (VCC) of mCMV (FIG. 2A) and hEFla-hCMV (FIG. 2B) GS vectors expressing a monoclonal antibody (mAbl), and cell viability at Day 5 post-transfection of mCMV (FIG. 2C) and hEFla-hCMV (FIG. 2D) GS vectors with different MSX concentrations (0-50 pM).Attorney Docket No. 0132-0386W01
[0019] FIGS. 3A-3D show fed-batch culture titers of mCMV (FIG. 3A) and hEFla-hCMV (FIG. 3B) GS vectors expressing mAbl, and glutamine concentration in cell culture media at Day 10 of fed-batch culture of mCMV (FIG. 3C) and hEFla-hCMV (FIG. 3D) GS vectors.
[0020] FIGS. 4A-4D show fed-batch culture titer of hEFla-hCMV GS vectors expressing a monoclonal antibody (mAb2) (FIG. 4A) and a bispecific antibody (bsAbl) (FIG. 4B), and glutamine concentration in cell culture media at Day 10 of fed-batch culture of hEFla-hCMV GS vectors expressing mAb2 (FIG. 4C) and bsAbl (FIG. 4D).
[0021] FIGS. 5A-5B show fed-batch culture titer of mCMV (FIG. 5A) and hEFla-hCMV GS vectors (FIG. 5B) with 7 x repeat copies of an AU-rich element.
[0022] FIGS. 6A-6H show fed-batch culture titer of mCMV and / or hEFla-hCMV GS vectors expressing mAbl (FIG. 6 A), mAb2 (FIG. 6B), mAb3 (FIG. 6C), mAb4 (FIG. 6D), bsAbl (FIG. 6E), bsAb2 (FIG. 6F), bsAb3 (FIG. 6G), and bsAb4 (FIG. 6H) over 30 days in culture.
[0023] FIGS. 7A-7F show the glycosylation profile of mAbl (FIG. 7A), mAb2 (FIG. 7B), mAb4 (FIG. 7C), bsAbl (FIG. 7D), bsAb2 (FIG. 7E), and bsAb3 (FIG. 7F) expressed using hEFla-hCMV GS vectors.
[0024] FIGS. 8A-8G show the percentage of monomer of mAbl (FIG. 8A), mAb2 (FIG. 8B), mAb3 (FIG. 8C), mAb4 (FIG. 8D), bsAbl (FIG. 8E), bsAb2 (FIG. 8F), andbsAb3 (FIG. 8G) expressed using hEFla-hCMV GS vectors.
[0025] FIGS. 9A-9D show the percentage of correctly assembled product of bsAbl (FIG. 9A), bsAb2 (FIG. 9B), bsAb3 (FIG. 9C), and bsAb4 (FIG. 9D) expressed using hEFla-hCMV GS vectors.
[0026] FIG. 10A shows the relative cell-specific productivity, expressed as rQp and measured by the BEACON® Optofluidic system, for clones derived from pools generated using hEFla-hCMV GS vectors. FIG. 10B shows the fed-batch titer of top 22 clones for each vector, together with the two pools from which they were derived (open bars).
[0027] FIG. 11 shows the fed-batch titers of the top 17 clones for the SV40 vector with the mCMV promoter, 20 clones for the SV40 vector with the hEFla-hCMV promoter, and 23 clones for the Ori vector with the hEFla-hCMV promoter.Attorney Docket No. 0132-0386W01DETAILED DESCRIPTION OF THE INVENTION
[0028] It should be understood that various aspects disclosed herein may be combined in different combinations than the combinations specifically presented in the description and accompanying drawings. It should also be understood that, depending on the example, certain acts or events of any of the processes or methods described herein may be performed in a different sequence, may be added, merged, or left out altogether (e.g., all described acts or events may not be necessary to carry out the techniques).
[0029] Unless otherwise defined herein, scientific and technical terms used in the present disclosure shall have the meanings that are commonly understood by one of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0030] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0031] The use of the term "or" in the claims is used to mean "and / or," unless explicitly indicated to refer only to alternatives or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and / or."
[0032] As used herein, the terms "comprising" (and any variant or form of comprising, such as "comprise" and "comprises"), "having" (and any variant or form of having, such as "have" and "has"), "including" (and any variant or form of including, such as "includes" and "include") or "containing" (and any variant or form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited, elements or method steps.
[0033] The use of the term "for example" and its corresponding abbreviation "e.g." means that the specific terms recited are representative examples and embodiments of the disclosure that are not intended to be limited to the specific examples referenced or cited unless explicitly stated otherwise.
[0034] As used herein, "about" can mean plus or minus 10% of the provided value. Where ranges are provided, they are inclusive of the boundary values. "About" can additionally or alternately mean either within 10% of the stated value, or within 5% of the stated value, or in some cases within 2.5% of the stated value; or, "about" can mean rounded to the nearest significant digit.Attorney Docket No. 0132-0386W01
[0035] As used herein, "between" is a range inclusive of the ends of the range. For example, a number between x and y explicitly includes the numbers x and y and any numbers that fall within x and y.
[0036] The terms "identical" or percent "identity" in the context of two or more nucleic acids or polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity. The percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignments of amino acid or nucleotide sequences. One such non-limiting example of a sequence alignment algorithm is the algorithm described in Karlin S., et al, (1990), as modified in Karlin S., et al., (1993), and incorporated into the NBLAST and XBLAST programs. In certain embodiments, Gapped BLAST can be used as described in Altschul SF, et al., (1997). BLAST-2, WU-BLAST-2 (Altschul SF, et al., (1996)), ALIGN, ALIGN-2 (Genentech, South San Francisco, California) or Megalign (DNASTAR) are additional publicly available software programs that can be used to align sequences.
[0037] The terms "5'" and "3'" as used herein refer to the directionality, i.e., the end-to-end chemical orientation of a single strand of nucleic acid. The chemical convention of naming carbon atoms in the nucleotide sugar-ring numerically gives rise to a 5 '-end and a 3 '-end. The relative positions of structures along a strand of nucleic acid, including genes and various protein binding sites, are usually noted as being either upstream (towards the 5 '-end) or downstream (towards the 3 '-end).
[0038] As used herein, the term "vector" refers to a nucleic acid molecule used as a vehicle to artificially carry foreign genetic material into a target cell, where it can be replicated and / or expressed. The four major types of vectors are plasmids, viral vectors, cosmids, and artificial chromosomes. Engineered vectors generally include an origin of replication, a multi cloning site, and a selectable marker, which can be referred to as the "backbone" of the vector.Engineered vectors can also include a transgene, e.g., a gene of interest (GO I), which can be referred to as the "insert". The purpose of a vector is typically to isolate, multiply, and / or express the insert in the target cell. In embodiments, the vector is a plasmid. In some embodiments, a "viral vector" as described herein refers to a vector derived from a virus,Attorney Docket No. 0132-0386W01which utilizes the virus' natural ability to infect cells to deliver genetic material into cells, e.g., for gene therapy or research purposes.
[0039] As used herein, the term "polynucleotide" (used herein interchangeably with the terms "nucleic acid," "nucleic acid molecule," and "oligonucleotide") refers to a linear polymer composed of at least two nucleotide units, which may be nucleic acids such as DNA and RNA, linked together by phosphodiester bonds. As used herein, the term "base pair" or "bp" refers to a pair of complementary nucleotides, e.g., adenine-thymine (or adenine-uracil in RNA) and cytosine-guanine pairs. The lengths of polynucleotides herein may be denoted as having a certain number of base pairs.
[0040] As used herein, the term "bacterial origin of replication (Ori)" is a specific DNA sequence within a vector where replication begins, allowing the vector to be duplicated within bacterial cells.
[0041] As used herein, the term "cryptic transcription start site" or "cryptic TSS" refers to an unintended or hidden site within a vector or element of a vector where transcription can initiate in mammalian cells.
[0042] As used herein, the term "cryptic TATA box" refers to an unintended or hidden binding site for the TATA-binding protein and / or other transcription factors that typically comprises a consensus sequence of repeating T and A base pairs, also known as a "TATA box," which can initiate transcription in mammalian cells. In some embodiments, a bacterial Ori comprises a cryptic TSS and / or a cryptic TATA box (Lemp, et al., Nucleic Acids Research, 40(15):7280-7290 (2012)). In some embodiments, the Ori is a bacterial element, but the cryptic TSS and / or a cryptic TATA box within the Ori is recognized by transcription machinery in mammalian cells in order to drive transcription.
[0043] As used herein, the term "transcriptional control element" refers to a DNA sequence that regulates the transcription of a gene, e.g., by serving as a binding site for transcription factors and other proteins, which may influence the rate and timing of gene expression. In some embodiments, transcriptional control elements of the present disclosure comprise promoter and / or enhancer elements, which may be arranged in any orientation. Exemplary transcriptional control elements are described, e.g., in WO 2025 / 144779, which is incorporated herein by reference in its entirety.
[0044] As used herein, an "enhancer" is a short regulatory DNA sequence that can increase the transcription of a gene by providing binding sites for transcription factors and otherAttorney Docket No. 0132-0386W01regulatory proteins. Naturally-occurring enhancers are often located at a distance from the genes they regulate as well as the promoters associated with these genes. In some embodiments, the enhancers of the present disclosure comprise at least 2, but not more than 6, binding sites for the transcription factor NFKB.
[0045] In general, the term "promoter" refers to a DNA sequence that initiates transcription of a particular gene, providing a binding site for RNA polymerase and transcription factors to regulate gene expression. The choice of promoter allows for control of the level of expressed protein, such as a GOI. The terms "core promoter" or "minimal promoter" refer to the minimal portion of the promoter required to initiate transcription and containing specific motifs recognized by the host's transcription machinery.
[0046] As used herein, the term "operably linked" is used to describe the functional connection between genetic elements, such as a promoter and a gene, ensuring that the gene is expressed in response to the promoter's activity. Elements that are operably linked are aligned together on the same nucleic acid molecule, as described herein.
[0047] As used herein, the term "AU-rich element (ARE)" refers to a sequence found in the 3' untranslated region of many mRNAs that influences mRNA stability and degradation, playing a role in post-transcriptional regulation. An ARE can cause degradation of the mRNA and thus decrease expression of the protein it encodes.
[0048] The term "selectable marker" refers to a gene introduced into a bacterial or eukaryotic cell that confers a trait suitable for artificial selection, such as antibiotic resistance, allowing for the identification of successfully modified cells.
[0049] The terms "protein," peptide," and "peptide" are used interchangeably herein to refer to a polymer of amino acids. A large, complex molecule composed of one or more chains of amino acids, essential for the structure, function, and regulation of the body's tissues and organs. The polymer can be linear or branched, can comprise modified amino acids, and can be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.Attorney Docket No. 0132-0386W01
[0050] As used herein, the term "stably integrated" refers to the permanent or substantially permanent incorporation of a foreign DNA sequence into the genome of a host cell, allowing for consistent expression of the introduced gene across cell generations.
[0051] The terms "host cell" or "host cell line" as used herein include any cells which are capable of growing in culture and either expressing a desired recombinant product protein or reproducing a polynucleotide, e.g., a vector, described herein. In some embodiments, a derived cell is a cell derived from a parental cell line through limiting dilution. In some embodiments, the host cells comprise mammalian cells, e.g., CHO cells, human cells, human kidney cells, HEK293 cells, or HEK293 SF cells. In some embodiments, the host cell is a CHO cell or CHO derived cell. In some embodiments, the host cell is a CHO cell comprising a knockout of its glutathione synthetase (GS) gene, also referred to as a "GS-KO" cell. In some embodiments, the host cell is a CHOK1SV cell. In some embodiments, the host cell is a CHOK1SV GS-KO cell. In some embodiments, the host cell is a human cell or human derived cell. In some embodiments, the host cell is a human kidney cell. In some embodiments, the human cell is a HEK293 cell. In some embodiments, the human cell is a HEK293 SF cell.
[0052] As used herein, the terms "selecting" or "selection" refer to the process of identifying and / or propagating cells or organisms with desired traits, using selectable markers or environmental conditions to favor the growth of specific variants. In some embodiments, selection is used to favor the growth of cells that have stably integrated a vector.
[0053] As used herein, the term "transfection" refers to the process of introducing nucleic acids into cells to study gene function and expression, often through chemical, physical, or viral methods. Suitable transfection methods for the cells described herein are known to one of ordinary skill in the art.
[0054] As used herein, the term "culturing" refers to the process of growing cells, tissues, or microorganisms under controlled conditions, typically in a laboratory setting, to produce biological products.
[0055] The term "methionine sulfoximine (MSX)" as used herein refers to a chemical compound that acts as an inhibitor of glutamine synthetase, used as a selective agent in cell culture.
[0056] A polypeptide, antibody, polynucleotide, vector, cell, or composition, that is "isolated" is a polypeptide, antibody, polynucleotide, vector, cell, or composition, that is in aAttorney Docket No. 0132-0386W01form not found in nature. Isolated polypeptides, antibodies, polynucleotides, vectors, cells or compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature. In some embodiments, an isolated antibody, polynucleotide, vector, cell, or composition is substantially pure. In some embodiments, an antibody of the present disclosure is a monospecific antibody. In some embodiments, an antibody of the present disclosure is a bispecific antibody.
[0057] The present invention relates to expression vectors for use in recombinant protein production. The expression vectors are useful for expressing proteins of interest (POI) in a host cell, such as a mammalian cell. In one embodiment, the expression vector comprises a bacterial origin of replication (Ori) comprising a cryptic TATA box and / or a cryptic transcription start site (TSS), wherein the Ori is operably linked to a glutamine synthetase gene; and a transcriptional control element comprising an enhancer nucleotide sequence and a mammalian endogenous promoter, wherein the transcriptional control element is operably linked to a gene of interest (GOI).
[0058] The expression vector of the present disclosure utilizes a bacterial Ori containing a cryptic TSS as the core promoter for GS expression ("minimal GS promoter") in a host cell, and a transcriptional control element (TCE) located downstream of the Ori and GS on the expression vector and comprising an enhancer and a mammalian promoter, wherein the enhancer is capable of enhancing both the Ori and the mammalian promoter. The ability of the enhancer to act in an orientation-independent matter, i.e., enhancing both the minimal GS promoter upstream and the mammalian promoter downstream, advantageously allows for the Ori and the TCE to perform dual functions: the Ori is both a site for plasmid replication and a minimal GS promoter; and the TCE both drives expression of the GOI and acts as an enhancer for GS expression from the minimal GS promoter. Schematics of expression vectors as described herein are shown in FIGS. IB and 1C.
[0059] As shown in FIGS. 1A-1C, the expression vectors of the present disclosure are simpler with fewer elements, due to the dual roles of the Ori and TCE. This results in a reduced vector size, which is easier to manufacture, enhances transfection efficiency, and reduces transfection toxicity, aiding in stable pool recovery. In some embodiments, the expression vector of the present disclosure is about 330 to about 350 bp smaller as compared to a conventional GS expression vector. In some embodiments, the expression vector of the present disclosure is about 340 to about 345 bp smaller as compared to a conventional GS expression vector. In some embodiments, the expression vector of the present disclosure isAttorney Docket No. 0132-0386W01about 340 bp smaller as compared to a conventional GS expression vector. In some embodiments, the expression vector of the present disclosure is about 345 bp smaller as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises one fewer genetic element as compared to a conventional GS expression vector. In some embodiments, the expression vector does not comprise a viral promoter. In some embodiments, the expression vector does not comprise the SV40 promoter.
[0060] It was found that the minimal GS promoter and its enhancement by the enhancer of the downstream, dual-role TCE, advantageously provides increased control of GS expression, which allows for a stringent GS selection system that does not require selection markers, e.g., MSX, for stable pool generation, in contrast to conventional GS expression vectors. An MSX-free system is highly desirable due to its association with increased long-term expression stability. It was further found that the expression vectors of the present disclosure, which remove the need for MSX, had similar or better stable pool recovery time and product titer as compared to conventional vectors requiring MSX.
[0061] In some embodiments, the expression vector of the present disclosure comprises (a) an Ori comprising a cryptic TATA box and / or a cryptic TSS, wherein the Ori is operably linked to a glutamine synthetase gene; and (b) a transcriptional control element comprising (i) an enhancer nucleotide sequence comprising about 300 to about 410 nucleotides of a human cytomegalovirus (hCMV) sequence; and (ii) a mammalian endogenous promoter, wherein the transcriptional control element is operably linked to a GOI. An exemplary expression vector of the present disclosure is shown in FIG. IB.
[0062] In some embodiments, the Ori is any suitable bacterial origin of replication, such as those derived from E. coli or other gram-negative bacteria. Exemplary Ori sequences include pMBl, ColEl, R6K, pl5A, pSClOl, CloDF13, or derivatives thereof (See, e.g., Morgan, K., "Plasmids 101: Origin of Replication," Addgene, (2014)). In some embodiments, the Ori is any one of pMBl, ColEl, pl 5 A, or CloDF13. In some embodiments, the Ori is pMBl. In some embodiments, the Ori comprises a cryptic TATA box and / or a cryptic TSS that are capable of expressing the glutamine synthetase gene operably linked thereto (Lemp, et al., Nucleic Acids Research, 40(15):7280-7290 (2012)). As discussed herein, the Ori is abacterial element for replication, but the cryptic TATA box and / or cryptic TSS within the Ori is recognized by mammalian cells to initiate transcription. In some embodiments, the cryptic TATA box comprises SEQ ID NO: 23. In some embodiments, the cryptic TSS comprises SEQ ID NO: 24. In some embodiments, the cryptic TATA box and / or cryptic TSS compriseAttorney Docket No. 0132-0386W01sequences found in an Ori selected from pMBl, ColEl, pl 5 A, and CloDF13. In some embodiments, the Ori comprises any one of SEQ ID NO: 17-22. In some embodiments, the Ori comprises any one of SEQ ID NO: 17-20. In some embodiments, the Ori comprises a sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NO: 17-22. In some embodiments, the Ori comprises a sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NO: 17-20.
[0063] In some embodiments, the glutamine synthetase gene is any suitable gene encoding an enzyme that catalyzes the synthesis of glutamine, e.g., from glutamate and ammonia. In some embodiments, the glutamine synthetase gene is a mammalian gene, such as a human, mouse, or Chinese hamster glutamine synthetase gene. In some embodiments, the glutamine synthetase gene comprises SEQ ID NO: 25. In some embodiments, the glutamine synthetase gene comprises a sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 25. In some embodiments, the glutamine synthetase gene is operably linked to the Ori described herein.
[0064] In some embodiments, the enhancer nucleotide sequence is any suitable enhancer element that increases transcription of the POI. In some embodiments, the enhancer nucleotide sequence comprises a viral enhancer sequence. In some embodiments, the enhancer nucleotide sequence comprises a cytomegalovirus (CMV) enhancer sequence. In some embodiments, the enhancer nucleotide sequence comprises a murine cytomegalovirus (mCMV) enhancer sequence ("mCMV enhancer"). In some embodiments, the mCMV enhancer comprises about 200 to about 300 nucleotides. In some embodiments, the mCMV enhancer comprises about 210 to about 250 nucleotides. In some embodiments, the mCMV enhancer comprises about 210 to about 230 nucleotides. In some embodiments, the mCMV enhancer comprises about 210 to about 250 nucleotides. In some embodiments, the mCMV enhancer comprises about 210 to about 230 nucleotides. In some embodiments, the mCMV enhancer comprises a nucleotide sequence with at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 7 In some embodiments, the mCMV enhancer comprises about 210 to about 222 nucleotides of a nucleotide sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 7. In some embodiments, the mCMV enhancer comprises about 3 to about 6 NFKB binding sites. In some embodiments, the mCMV enhancer is capable of enhancing transcriptional activity of the Ori as described herein. In some embodiments, the mCMVAttorney Docket No. 0132-0386W01enhancer is capable of enhancing expression of the glutamine synthetase gene that is operably linked to the Ori as described herein. In some embodiments, enhancing the expression of the glutamine synthetase gene increases expression of the glutamine synthetase gene, thereby increasing glutamine concentration.
[0065] In some embodiments, the transcriptional control element described herein comprises a human cytomegalovirus (hCMV) enhancer nucleotide sequence ("hCMV enhancer"). In some embodiments, the hCMV enhancer comprises about 300 to about 410 nucleotides. In some embodiments, the hCMV enhancer comprises about 350 to about 410 nucleotides. In some embodiments, the hCMV enhancer comprises about 390 to about 410 nucleotides. In some embodiments, the hCMV enhancer comprises about 400 to about 410 nucleotides. In some embodiments, the hCMV enhancer comprises about 407 nucleotides. In some embodiments, the hCMV enhancer comprises a nucleotide sequence with at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NO: 8-9. In some embodiments, the hCMV enhancer comprises about 400 to about 410 nucleotides of a nucleotide sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NO: 8-9. In some embodiments, the hCMV enhancer comprises about 2 to about 6 NFKB binding sites. In some embodiments, the hCMV enhancer comprises about 2 or about 3 NFKB binding sites. In some embodiments, the hCMV enhancer is capable of enhancing transcriptional activity of the Ori as described herein. In some embodiments, the hCMV enhancer is capable of enhancing expression of the glutamine synthetase gene that is operably linked to the Ori as described herein.
[0066] In some embodiments, the mammalian endogenous promoter is any suitable promoter that drives expression of the GOI in a host cell. In some embodiments, the mammalian endogenous promoter comprises a human promoter sequence. In some embodiments, the mammalian endogenous promoter comprises a promoter sequence endogenous to human embryonic kidney (HEK) cells. In some embodiments, the mammalian endogenous promoter comprises a mouse promoter sequence. In some embodiments, the mammalian endogenous promoter comprises a Chinese hamster promoter sequence. In some embodiments, the mammalian endogenous promoter comprises a promoter sequence endogenous to Chinese hamster ovary (CHO) cells. In some embodiments, the mammalian endogenous promoter comprises a mammalian core promoter.
[0067] In some embodiments, the mammalian endogenous promoter comprises a human EFla (hEFla) promoter. In embodiments, the mammalian endogenous promoter comprises aAttorney Docket No. 0132-0386W01human EFla core promoter sequence. In some embodiments, the mammalian endogenous promoter comprises about 150 to about 250 nucleotides of the human EFla promoter sequence. In some embodiments, the mammalian endogenous promoter comprises about 180 to about 220 nucleotides of the human EFla promoter sequence. In some embodiments, the mammalian endogenous promoter comprises about 200 to about 210 nucleotides of the human EFla promoter sequence. In some embodiments, the mammalian endogenous promoter comprises about 203 nucleotides of the human EFla promoter sequence. In some embodiments, the mammalian endogenous promoter comprises a nucleotide sequence with at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 5. In some embodiments, the mammalian endogenous promoter comprises about 200 to about 210 nucleotides of a nucleotide sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 5.
[0068] In some embodiments, the mammalian endogenous promoter comprises a CHO promoter. In some embodiments, the CHO promoter comprises chGAPDH, chGRP78, chS100a6, or chEFla. In some embodiments, the CHO promoter comprises the core promoter region of chGAPDH, chGRP78, chS100a6, or chEFla. In some embodiments, the mammalian endogenous promoter comprises a nucleotide sequence with at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1-6.
[0069] In some embodiments, the TCE comprises an hCMV enhancer described herein and a human EFla promoter. In some embodiments, the TCE comprises about 400 to about 800 nucleotides. In some embodiments, the TCE comprises about 500 to about 700 nucleotides. In some embodiments, the TCE comprises about 560 to about 660 nucleotides. In some embodiments, the TCE comprises about 600 to about 620 nucleotides. In some embodiments, the TCE comprises about 610 nucleotides. In some embodiments, the TCE comprises a nucleotide sequence with at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NO: 10-16. In some embodiments, the TCE comprises about 600 to about 620 nucleotides of a nucleotide sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NO: 10-16. In some embodiments, the TCE is capable of enhancing expression of the glutamine synthetase gene operably linked to the Ori as described herein.
[0070] In some embodiments, the expression vector described herein additionally comprises an AU-rich element. The AU-rich element is a sequence motif that is recognized by RNA-binding proteins and can influence mRNA stability and translation efficiency. In someAttorney Docket No. 0132-0386W01embodiments, the AU-rich element is located downstream of the glutamine synthetase gene. In some embodiments, the AU-rich element is located between the glutamine synthetase gene and a 3' polyadenylation sequence. In some embodiments, the AU-rich element comprises SEQ ID NO: 26. In some embodiments, the AU-rich element comprises a nucleotide sequence with at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 26. In some embodiments, the expression vector comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 copies of an AU-rich element. In some embodiments, the expression vector comprises 1 to 11 copies of an AU-rich element. In some embodiments, the expression vector comprises 7 copies of an AU-rich element.
[0071] In another embodiment, the expression vector described herein additionally comprises a selectable marker for bacterial expression. The selectable marker can be any suitable gene that confers resistance to an antibiotic or other selective agent. In some embodiments, the selectable marker is an antibiotic resistance gene. In some embodiments, the antibiotic resistance gene comprises a gene that confers resistance to ampicillin, kanamycin, chloramphenicol, tetracycline, or combinations thereof. In some embodiments, the selectable marker is an ampicillin resistance gene.
[0072] In some embodiments, the TCE described herein is operably linked to a GOI. In some embodiments, the TCE directs expression of the GOI. In some embodiments, the GOI encodes a protein of interest (POI). In some embodiments, the POI is a therapeutic protein of interest. In some embodiments, the POI is an antibody or antigen-binding fragment thereof, a fusion protein, an immunoglobulin, an engineered protein, a protein fragment or an enzyme. In another embodiment, the POI is monospecific antibody, a bispecific antibody, or a multispecific antibody, or antigen-binding fragments thereof.
[0073] A "conventional GS expression vector" as described herein comprises separate promoters for the GS and GOI, wherein the promoters do not enhance one another. A conventional GS expression suitably does not comprise an Ori operably linked to the GS gene. A conventional GS expression vector can also include the GS gene operably linked to a promoter that is not enhanced by any other promoter present on the vector. A conventional GS expression vector can also include a first promoter operably linked to the GS gene, a second promoter operably linked to the GOI, and a third promoter for plasmid replication, wherein the first, second, and third promoters are not enhanced by one another. An exemplary conventional GS expression vector is depicted in FIG. 1 A. In some embodiments, the expression vector described herein is more compact, i.e., comprises fewer nucleotidesAttorney Docket No. 0132-0386W01and / or fewer genetic elements as compared to a conventional GS expression vector.However, despite having fewer genetic elements, the expression vector described herein provides comparable or increased GOI expression, and / or more stable POI titer, as compared to the conventional GS expression vector. This is achieved, for example, by utilizing its genetic elements more efficiently, e.g., leveraging the surprising ability of the TCE for expressing the GOI to also enhance the expression of the GS gene from the Ori.
[0074] As depicted in FIG. 1 A, the conventional GS expression vector comprises an SV40E promoter operably linked to the glutamine synthetase gene and a separate Ori, while the expression vector described herein comprises the Ori operably linked to a glutamine synthetase gene. The SV40E promoter is about 345 nucleotides in length. In some embodiments, the expression vector comprises about 330 to about 350 fewer nucleotides as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises about 340 to about 345 fewer nucleotides as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises about 345 fewer nucleotides as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises one fewer genetic element as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises about 345 fewer nucleotides and / or one fewer genetic element as compared to a conventional GS expression vector. Advantages of a smaller expression vector are further described herein and include, e.g., improving transfection efficiency and reducing transfection toxicity, both of which aid in stable pool recovery.
[0075] In some embodiments, the expression vector of the present disclosure is used in a method for selecting a cell that expresses a GOI. In some embodiments, the present disclosure provides a method for selecting a cell that expresses a GOI, comprising transfecting the expression vector described herein into a cell that lacks glutamine synthetase; and culturing the transfected cells under conditions that select for cells which stably integrate the vector.
[0076] The expression vector may be introduced into a host cell using any suitable method, such as electroporation, lipofection, or calcium phosphate transfection. In some embodiments, the expression vector is introduced into the host cell by transfection. In some embodiments, the transfected cell is cultured under conditions stably integrate the vector, thereby generating the stably integrated cells. In some embodiments, the culture conditions can include any suitable medium, temperature, and other parameters that support growth andAttorney Docket No. 0132-0386W01protein production by the cell. In some embodiments, the stably integrated cell produces high levels of the POI.
[0077] In some embodiments, the transfected cell is cultured under conditions that select for cells which stably integrate the vector, thereby enriching for cells that produce high levels of the POI. In some embodiments, the method comprises selecting cells that express a GOI using a selectable marker. In some embodiments, the selected cells are cultured under conditions that select for cells which stably integrate the vector, thereby enriching for cells that produce high levels of the POI.
[0078] In some embodiments, the culture conditions include a selective agent, such as an antibiotic or a nutrient deprivation, to select for cells that have stably integrated the expression vector. In some embodiments, the selectable marker is the GS gene. In such embodiments, the cells are cultured in the absence of glutamine to select for cells that express the glutamine synthetase enzyme. In conventional GS expression systems, MSX is used to select for cells that stably integrate and express GS from the expression vector. In some embodiments, MSX is not used in the culturing of the transfected cells, thereby simplifying the selection process while increasing long-term expression stability.
[0079] In some embodiments, the present disclosure provides a stably integrated cell comprising the expression vectors described herein. In some embodiments, the stably integrated cell is selected by the method described above.
[0080] In some embodiments, the cell is a mammalian cell. In some embodiments, the mammalian cell comprises a CHO cell or CHO derived cell, a human cell, a human kidney cell, a HEK293 cell, or a HEK293 SF cell. In some embodiments, the mammalian cell comprises a CHO cell or CHO derived cell. In some embodiments, the cell is capable of performing complex post-translational modifications and producing high levels of the POI. In some embodiments, the CHO cell comprises a deletion of an endogenous glutamine synthetase gene, thereby reducing background expression of glutamine synthetase and increasing the stringency of selection for cells that have stably integrated the expression vector. In some embodiments, the CHO cell is a CHOK1SV cell. In some embodiments, the CHO cell is a CHOK1SV GS-KO cell.
[0081] In some embodiments, the present disclosure also provides a method for expressing a POI from the vector described herein in a host cell, e.g., the stably integrated cell described herein. The method involves culturing the stably integrated cell under suitable conditions to produce a POI. In some embodiments, the POI is a therapeutic protein of interest. In someAttorney Docket No. 0132-0386W01embodiments, the POI is an antibody or antigen-binding fragment thereof, a fusion protein, an immunoglobulin, an engineered protein, a protein fragment or an enzyme. In some embodiments, the POI is monospecific antibody, a bispecific antibody, or a multi-specific antibody, or antigen-binding fragments thereof. In some embodiments, the POI is used in research and development applications. In some embodiments, the POI is a reagent for a biochemical assay and / or an antigen for an immunological assay. In some embodiments, the POI is used in cell-based therapy and / or gene therapy applications. In some embodiments, the POI is a vaccine.
[0082] In some embodiments, the methods described herein provide increased control of GS expression compared to a method utilizing a conventional GS expression vector. As discussed herein, the TCE of the expression vector provides increased control of expression of the glutamine synthetase gene operably linked to the Ori within the expression vector, which, in some embodiments, provides increased control of GS expression as compared to a method utilizing a conventional GS expression vector. Increased control of GS expression allows for more stringent selection as compared to a method utilizing a conventional GS expression vector. In some embodiments, the increased selection stringency of the method described herein allows for a method that does not comprise culturing and / or selection with MSX, as compared to a method utilizing the conventional GS expression vector requiring MSX. Advantages of MSX-free selection method are further described herein.
[0083] In some embodiments, the methods described herein produce at least 1.5-fold higher titer of the POI after 30 days in culture as compared to a method utilizing a conventional GS expression vector as described herein, e.g., as depicted in FIG. 1 A, in which the Ori is not operably linked to the GS gene, and in which expression of the GS gene is not enhanced by any regulatory element operably linked to the GOI. In some embodiments, the method of expressing a POI produces at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0-fold higher titer of the POI after 30 days in culture as compared to a method utilizing a conventional GS expression vector. In some embodiments, the method described herein does not comprise culturing and / or selection with MSX, and the method utilizing the conventional GS expression vector comprises culturing and selection with MSX.
[0084] In some embodiments, the method of expressing a POI produces stable POI titers over 30 days in culture. In some embodiments, the method of expressing a POI produces POI titers that are more stable over 30 days in culture as compared to a method utilizing a conventional GS expression vector. In some embodiments, the methods described herein produce less thanAttorney Docket No. 0132-0386W01about 15% change in titer of a stable pool of the POI after 30 days in culture as compared to a method utilizing a conventional GS expression vector as described herein. In some embodiments, the method of expressing a POI produces less than about 25%, 20%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% change in titer of a stable pool of the POI after 30 days in culture as compared to a method utilizing a conventional GS expression vector. In some embodiments, the method of expressing a POI produces POI titers that exhibit less than about a 15% change in titer after 30 days in culture. In some embodiments, the method of expressing a POI produces POI titers that exhibit less than about a 15% change in titer after 30 days in culture as compared to a method utilizing a conventional GS expression vector, which exhibits a greater than about a 15% change in titer after 30 days in culture.
[0085] In some embodiments, the methods described herein further comprise isolating the POI, e.g., from the culture medium and / or cell lysate. In some embodiments, the POI is isolated from the culture medium or cell lysate using any suitable purification technique, such as chromatography, filtration, crystallization, precipitation, and the like.
[0086] In some embodiments, the methods utilize an expression vector described herein comprising fewer nucleotides and / or fewer genetic elements as compared to a conventional GS expression vector as described herein. In some embodiments, the expression vector comprises about 330 to about 350 fewer nucleotides as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises about 340 to about 345 fewer nucleotides as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises about 345 fewer nucleotides as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises one fewer genetic element as compared to a conventional GS expression vector. In some embodiments, the expression vector comprises about 345 fewer nucleotides and / or one fewer genetic element as compared to a conventional GS expression vector.
[0087] The present invention is not limited to the specific embodiments described above, but rather encompasses all variations and combinations thereof that are within the scope of the claims. All references cited herein, including patents, patent applications, papers, textbooks and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety.Table 1: SequencesAttorney Docket No. 0132-0386W01Name Sequence SEQ ID NO.ACCACGAGAAGATCCTCAACTTTTCCACAGCCTTTGCATAAAGGGGAGAGGGTCG GCGGTGCAGCTGTGGCACACACGCACTTCTGCTCAACCCGCCCCCCCCCGCCCCC GTTCCTGTTCCTTCCCAGGTTCTCCCCATTTTATCGGGGCGGCAACTTTTAGGTC CCTGGGTCCTGGAAGTCCTTAGTACACACTCTTCGTCCTTAAGTCCATAGTCTGTchGAPDH ATTCCCTCGGTCCTATCCTGTCCCCCATCACCGGGTCACCTCCCCAGCGAAGCAA 1 promoter TCTCAGTTCCCCTCCCCCTCTCAGCCCCGAGCCCACACGTTTGGTGCGTGCACAT TTCAAAAACGAGGCGGGTCCAAAGAGAGGGGGTGGGGAGGTGCCGAGTGGCCCAG CTACTCGCGGCTTTACGGGTGCACGTAGCTCAGGCCTCAGCGCCCTTGAGCTGTG ACTGGATGGATGAGCGGGGCGGGAGGCGGGGCGAGCGTCCTCGGCGCTCCCCACC ACCCCAGTTCCTATAAATACGGACTGCAGCCCTCCCCGGT GGTTACCGGCGGAAACGGTCTCGGGTTGAGAGGTCACCTGAGATGCTGCCTCTCA TTGGCGGCCGTTGAGAGTAACCAGTAGCCAATGAGTCAGCCCGGGGGGCGTAGCGchGRP78GTGACGTAAGTTGCGGAGGAGGCCGCTTCGAATCGGCAGCGGCCAGCTTGGTGGC 2 promoterATGGACCAATCAGCGTCCTCCAACGAGAAGCGCCTTCACCAATCGGAGGCCTCCA CGACGGGGCTGGGGGGAGGGTATATAAGCCAAGTCGGCGGCGGCGCGCTCC ACACTGGCCAAGACAACAGTGACCGGAGGACCTGCCTTTGCGGCTCCGAGAGGTA AGCGCCGCGGCCTGCTCTTGCCAGACCTCCTTTGAGCCTGTCTCGTGGCTCCTCCchGRP78TGACCCGGGGGGCTTCTGTCGCCCTCAGATCGGAACGCCGCCGCGCTCCGGGACT 3 intronACAGCCTGTTGCTGGACTTCGAGACTGCAGACGGACCGACCGCTGAGCACTGGCC CACAGCGCCGGCAAG ATGCCGGAGTCACGAGTCACGTGCCATAAGGGCAAACTGAAGTATGGAAATTAGG GAAAACTCGATGTCTCTGGTTTGTGCTGGTCTCCCAGACCAGGGTCACTAGGCTC CCTCATGCCACTCCCAATCCGGGACAGTCCTGGCAGCAGAGGCGTGGAAAACTGAchS100a6GGGGGTTGTTGGGGTGTGTTTTGCTAGCCTCAGGCGCCGGGTGGGGCTCGGGGCG 4 promoterGGCCGGCACTCCTTGGGCGGGCCTCCCGGATGCTAGCCGCTATAAGGCCAGCCGG ACTGCGACACAGTCCATCCCCTCGACCACTCCTTTGGCTCTTCGCTGTCTACCTG CC CGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAhEFla GAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGG 5 promoter GTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGG GAGAAC C GT AT AT AAGT GCAGT AGT C GC C GT GAAC GT T GGAGGAGCCTGCGCCTAGGGCGGATCGCGGGTCGGCGGGAGAGCACAAGCCCACAchEFla GTCCCCGGCGGTGGGGGAGGGGCGCGCTGAGCGGGGGCCCGGGAGCCAGCGCGGG 6 promoter GCAAACTGGGAAAGTGGTGTCGTGTGCTGGCTCCGCCCTCTTCCCGAGGGTGGGG GAGAACGGTATAAAAGTGCGGTAGTCGCGTTGGACGTTmCMV TACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAG enhancer GGGT GAAT CAACAGGAAAGTCCCATTGGAGCCAAGTACACTGAGT CAATAGGGAC with NFKB TTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTT 7 binding TTTCCCATTATTGGCACGTACATAAGGTCAATAGGGGTGAGTCATTGGGTTTTTC sites GA CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCChCMV GC C CAT T GAC GT CAAT AAT GAC GT AT GT T C C CATAGTAACGCCAATAGGGACTTT enhancer CCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACAT with 3 CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC 8 NFKB CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAbinding CATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATC sites AATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTG ACGTCAATGGGAGTTTGTTTTGTruncated CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCC hCMV GC C CAT T GAC GT CAAT AAT GAC GT AT GT T C C CATAGTAACGCCAATAGGGACTTT enhancer CCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACAT with 2 CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC 9 NFKB CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAbinding CATCTACGTATTAGTCATCGCTATTACsitesTACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAGchGAPDH- GGGT GAAT CAACAGGAAAGT CCCATT GGAGCCAAGTACACT GAGT CAATAGGGAC 10 mCMVTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTTAttorney Docket No. 0132-0386W01TTTCCCATTATTGGCACGTACATAAGGTCAATAGGGGTGAGTCATTGGGTTTTTC CAACCACGAGAAGATCCTCAACTTTTCCACAGCCTTTGCATAAAGGGGAGAGGGT CGGCGGTGCAGCTGTGGCACACACGCACTTCTGCTCAACCCGCCCCCCCCCGCCC CCGTTCCTGTTCCTTCCCAGGTTCTCCCCATTTTATCGGGGCGGCAACTTTTAGG TCCCTGGGTCCTGGAAGTCCTTAGTACACACTCTTCGTCCTTAAGTCCATAGTCT GTATTCCCTCGGTCCTATCCTGTCCCCCATCACCGGGTCACCTCCCCAGCGAAGC AATCTCAGTTCCCCTCCCCCTCTCAGCCCCGAGCCCACACGTTTGGTGCGTGCAC ATTTCAAAAACGAGGCGGGTCCAAAGAGAGGGGGTGGGGAGGTGCCGAGTGGCCC AGCTACTCGCGGCTTTACGGGTGCACGTAGCTCAGGCCTCAGCGCCCTTGAGCTG TGACTGGATGGATGAGCGGGGCGGGAGGCGGGGCGAGCGTCCTCGGCGCTCCCCA CCACCCCAGTTCCTATAAATACGGACTGCAGCCCTCCCCGGT TACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAG GGGT GAAT CAACAGGAAAGT CCCATT GGAGCCAAGTACACT GAGT CAATAGGGAC TTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTT TTTCCCATTATTGGCACGTACATAAGGTCAATAGGGGTGAGTCATTGGGTTTTTC CAGGTTACCGGCGGAAACGGTCTCGGGTTGAGAGGTCACCTGAGATGCTGCCTCT CATTGGCGGCCGTTGAGAGTAACCAGTAGCCAATGAGTCAGCCCGGGGGGCGTAGchGRP78- CGGTGACGTAAGTTGCGGAGGAGGCCGCTTCGAATCGGCAGCGGCCAGCTTGGTGmCMV 11GCATGGACCAATCAGCGTCCTCCAACGAGAAGCGCCTTCACCAATCGGAGGCCTCintronCACGACGGGGCTGGGGGGAGGGTATATAAGCCAAGTCGGCGGCGGCGCGCTCCAC ACTGGCCAAGACAACAGTGACCGGAGGACCTGCCTTTGCGGCTCCGAGAGGTAAG CGCCGCGGCCTGCTCTTGCCAGACCTCCTTTGAGCCTGTCTCGTGGCTCCTCCTG ACCCGGGGGGCTTCTGTCGCCCTCAGATCGGAACGCCGCCGCGCTCCGGGACTAC AGCCTGTTGCTGGACTTCGAGACTGCAGACGGACCGACCGCTGAGCACTGGCCCA CAGCGCCGGCAAG TACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAG GGGT GAAT CAACAGGAAAGT CCCATT GGAGCCAAGTACACT GAGT CAATAGGGAC TTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTT TTTCCCATTATTGGCACGTACATAAGGTCAATAGGGGTGAGTCATTGGGTTTTTC CAATGCCGGAGTCACGAGTCACGTGCCATAAGGGCAAACTGAAGTATGGAAATTAchS100a6- GGGAAAACTCGATGTCTCTGGTTTGTGCTGGTCTCCCAGACCAGGGTCACTAGGC 12 mCMVTCCCTCATGCCACTCCCAATCCGGGACAGTCCTGGCAGCAGAGGCGTGGAAAACT GAGGGGGTTGTTGGGGTGTGTTTTGCTAGCCTCAGGCGCCGGGTGGGGCTCGGGG CGGGCCGGCACTCCTTGGGCGGGCCTCCCGGATGCTAGCCGCTATAAGGCCAGCC GGACTGCGACACAGTCCATCCCCTCGACCACTCCTTTGGCTCTTCGCTGTCTACC TGCC TACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAG GGGT GAAT CAACAGGAAAGT CCCATT GGAGCCAAGTACACT GAGT CAATAGGGAC TTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTThEFla - TTTCCCATTATTGGCACGTACATAAGGTCAATAGGGGTGAGTCATTGGGTTTTTC 13 mCMV CACGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCC GAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCG GGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGG GGGAGAAC C GT AT AT AAGT GCAGT AGT C GC C GT GAAC GT T CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCC GCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTT CCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACAT CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTA CATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATChEFla-hCMV 14AATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTG ACGTCAATGGGAGTTTGTTTTGCGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGC GCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGG TGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTC CGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGA ACGTT CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCC GCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTThEFla-hCMVCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACAT 15 ( short )CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAAttorney Docket No. 0132-0386W01CATCTACGTATTAGTCATCGCTATTACCGTGAGGCTCCGGTGCCCGTCAGTGGGC AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGA ACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACT GGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGC CGTGAACGTT CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCC GCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTT CCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACAT CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAchEFla- CATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATC 16 hCMV AATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTG ACGTCAATGGGAGTTTGTTTTGGGAGGAGCCTGCGCCTAGGGCGGATCGCGGGTC GGCGGGAGAGCACAAGCCCACAGTCCCCGGCGGTGGGGGAGGGGCGCGCTGAGCG GGGGCCCGGGAGCCAGCGCGGGGCAAACTGGGAAAGTGGTGTCGTGTGCTGGCTC CGCCCTCTTCCCGAGGGTGGGGGAGAACGGTATAAAAGTGCGGTAGTCGCGTTGG ACGTTpMBl Ori TTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAG AGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCT( Cryptic CCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTT TATA box TCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGT and TCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC cryptic CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACA 17 TSS in CGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTAT bold GTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA underline) GAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGT TGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTT TGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAColEl Ori TTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAG AGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCT( Cryptic CCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTT TATA box TCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGT and TCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC cryptic CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACA 18 TSS in CGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTAT bold GTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA underline) GGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGT TGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTT TGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAp!5A Ori TTTCCATAGGCTCCGCCCCCCTGACAAGCATCACGAAATCTGACGCTCAAATCAG TGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGCGGCT( Cryptic CCCTCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGGTGTCATTCCGCTGTT TATA box ATGGCCGCGTTTGTCTCATTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCG and CTCCAAGCTGGACTGTATGCACGAACCCCCCGTTCAGTCCGACCGCTGCGCCTTA 19 cryptic TCCGGTAACTATCGTCTTGAGTCCAACCCGGAAAGACATGCAAAAGCACCACTGG TSS in CAGCAGCCACTGGTAATTGATTTAGAGGAGTTAGTCTTGAAGTCATGCGCCGGTT bold AAGGCTAAACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAAGCCAGTTACC underline) TCGGTTCAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCG GT T T T T T C GT T T T C AGAG C AAGAGAT TACGCGCAGAC C AAAAC GAT C T C AACloDF13 TTTCCATAGGCTCCGCCCTCCTGCCAGAGTTCACATAAACAGACGCTTTTCCGGT Ori GCATCTGTGGGAGCCGTGAGGCTCAACCATGAATCTGACAGTACGGGCGAAACCC GACAGGACTTAAAGATCCCCACCGTTTCCGGCGGGTCGCTCCCTCTTGCGCTCTC CTGTTCCGACCCTGCCGTTTACCGGATACCTGTTCCGCCTTTCTCCCTTACGGGA AGTGTGGCGCTTTCTCATAGCTCACACACTGGTATCTCGGCTCGGTGTAGGTCGT TCGCTCCAAGCTGGGCTGTAAGCAAGAACTCCCCGTTCAGCCCGACTGCTGCGCC 20 TTATCCGGTAACTGTTCACTTGAGTCCAACCCGGAAAAGCACGGTAAAACGCCAC TGGCAGCAGCCATTGGTAACTGGGAGTTCGCAGAGGATTTGTTTAGCTAAACACG CGGTTGCTCTTGAAGTGTGCGCCAAAGTCCGGCTACACTGGAAGGACAGATTTGG TTGCTGTGCTCTGCGAAAGCCAGTTACCACGGTTAAGCAGTTCCCCAACTGACTT AACCTTCGATCAAACCACCTCCCCAGGTGGTTTTTTCGTTTACAGGGCAAAAGATTACGCGCAGAAAAAAAGGATCTCAAAttorney Docket No. 0132-0386W01R6K Ori TGTCAGCCGTTAAGTGTTCCTGTGTCACTCAAAATTGCTTTGAGAGGCTCTAAGG GCTTCTCAGTGCGTTACATCCCTGGCTTGTTGTCCACAACCGTTAAACCTTAAAA GCTTTAAAAGCCTTATATATTCTTTTTTTTCTTATAAAACTTAAAACCTTAGAGG CTATTTAAGTTGCTGATTTATATTAATTTTATTGTTCAAACATGAGAGCTTAGTA 21 CGTGAAACATGAGAGCTTAGTACGTTAGCCATGAGAGCTTAGTACGTTAGCCATG AGGGTTTAGTTCGTTAAACATGAGAGCTTAGTACGTTAAACTTGAGAGCTTAGTA C GT GAAACAT GAGAGCT T AGT AC GT ACpSClOl Ori GAGTTATACACAGGGCTGGGATCTATTCTTTTTATCTTTTTTTATTCTTTCTTTA TTCTATAAATTATAACCACTTGAATATAAACAAAAAAAACACACAAAGGTCTAGC GGAATTTACAGAGGGTCTAGCAGAATTTACAAGTTTTCCAGCAAAGGTCTAGCAG 22 AATTTACAGATACCCACAACTCAAAGGAAAAGGACTAGTAATTATCATTGACTAG CCCCryptic TATAAAGA 23 TATA boxCryptic AGCTCCCTtranscript 24 ion startsiteGlutamine ATGGCCACCTCAGCAAGTTCCCACTTGAACAAAAACATCAAGCAAATGTACTTGT synthetase GCCTGCCCCAGGGTGAGAAAGTCCAAGCCATGTATATCTGGGTTGATGGTACTGG cDNA AGAAGGACTGCGCTGCAAAACCCGCACCCTGGACTGTGAGCCCAAGTGTGTAGAA GAGTTACCTGAGTGGAATTTTGATGGCTCTAGTACCTTTCAGTCTGAGGGCTCCA ACAGTGACATGTATCTCAGCCCTGTTGCCATGTTTCGGGACCCCTTCCGCAGAGA TCCCAACAAGCTGGTGTTCTGTGAAGTTTTCAAGTACAACCGGAAGCCTGCAGAG ACCAATTTAAGGCACTCGTGTAAACGGATAATGGACATGGTGAGCAACCAGCACC CCTGGTTTGGAATGGAACAGGAGTATACTCTGATGGGAACAGATGGGCACCCTTT TGGTTGGCCTTCCAATGGCTTTCCTGGGCCCCAAGGTCCGTATTACTGTGGTGTG GGCGCAGACAAAGCCTATGGCAGGGATATCGTGGAGGCTCACTACCGCGCCTGCT TGTATGCTGGGGTCAAGATTACAGGAACAAATGCTGAGGTCATGCCTGCCCAGTG 25 GGAGTTCCAAATAGGACCCTGTGAAGGAATCCGCATGGGAGATCATCTCTGGGTG GCCCGTTTCATCTTGCATCGAGTATGTGAAGACTTTGGGGTAATAGCAACCTTTG ACCCCAAGCCCATTCCTGGGAACTGGAATGGTGCAGGCTGCCATACCAACTTTAG CACCAAGGCCATGCGGGAGGAGAATGGTCTGAAGCACATCGAGGAGGCCATCGAG AAACTAAGCAAGCGGCACCGGTACCACATTCGAGCCTACGATCCCAAGGGGGGCC TGGACAATGCCCGTCGTCTGACTGGGTTCCACGAAACGTCCAACATCAACGACTT TTCTGCTGGTGTCGCCAATCGCAGTGCCAGCATCCGCATTCCCCGGACTGTCGGC CAGGAGAAGAAAGGTTACTTTGAAGACCGCCGCCCCTCTGCCAATTGTGACCCCT TTGCAGTGACAGAAGCCATCGTCCGCACATGCCTTCTCAATGAGACTGGCGACGA GCCCTTCCAATACAAAAACTAA AU- rich TTATTTATT 26 elementOri-GS CGGTGCGGCCGCGACCTGCAGGCGCAGAACTGGTAGGTATGGAAGATCCCTCGAG 27 hEFla-hCMV ATCCATTGTGCTGGCGGTAGGCGAGCAGCGCCTGCCTGAAGCTGCGGGCATTCCC Vector GATCAGAAATGAGCGCCAGTCGTCGTCGGCTCTCGGCACCGAATGCGTATGATTC TCCGCCAGCATGGCTTCGGCCAGTGCGTCGAGCAGCGCCCGCTTGTTCCTGAAGT GCCAGTAAAGCGCCAACAAGCTTTAATTAACGCGTATACCTAGGATCCGGCCGGC CTGCAGGTGTCCTCACAGGAACGAAGTCCCTAAAGAAACAGTGGCAGCCAGGTTT AGCCCCGGAATTGACTGGATTCCTTTTTTAGGGCCCATTGGTATGGCTTTTTCCC CGTATCCCCCCAGGTGTCTGCAGGCTCAAAGAGCAGCGAGAAGCGTTCAGAGGAA AGCGATCCCGTGCCACCTTCCCCGTGCCCGGGCTGTCCCCGCACGCTGCCGGCTC GGGGATGCGGGGGGAGCGCCGGACCGGAGCGGAGCCCCGGGCGGCTCGCTGCTGC CCCCTAGCGGGGGAGGGACGTAATTACATCCCTGGGGGCTTTGGGGGGGGGCTGT CCCTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGA GGGTTAATTAGATCTTAATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCC CCCTCGAGGTCGACGGTATCGATAAGCTTGATATCTATAACAAGAAAATATATAT AT AAT AAGT TAT CAC GT AAGT AGAACAT GAAAT AACAAT AT AAT TAT C GT AT GAG TTAAATCTTAAAAGTCACGTAAAAGATAATCATGCGTCATTTTGACTCACGCGGT CGTTATAGTTCAAAATCAGTGACACTTACCGCATTGACAAGCACGCCTCACGGGA GCTCCAAGCGGCGACTGAGATGTCCTAAATGCACAGCGACGGATTCGCGCTATTT AGAAAGAGAGAGCAATATTTCAAGAATGCATGCGTCAATTTTACGCAGACTATCTTTCTAGGGTTAATCTAGCTGCATCAGGATCATATCGTCGGGTCTTTTTTCCGGCTAttorney Docket No. 0132-0386W01CAGTCATCGCCCAAGCTGGCGCTATCTGGGCATCGGGGAGGAAGAAGCCCGTGCC TTTTCCCGCGAGGTTGAAGCGGCATGGAAAGAGTTTGCCGAGGATGACTGCTGAT TAAAAAT GAAGTTTTAAAT CAAT CTAAAGTATATAT GAGTAAACTT GGT CT GAGA GTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTC ATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA CCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAG ATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGC AACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGT AGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGG TGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAG GCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCT CCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAG CACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCT TGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGC TCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTT GAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTT ACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAA AGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATA TTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGT ATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC CTCCCGCCTCGTTCATTCACGTTTTTGAACCCGTGGAGGACGGGCAGACTCGCGG TGCAAATGTGTTTTACAGCGTGATGGAGCAGATGAAGATGCTCGACACGCTGCAG AAC AC G C AG C T AGAT T AAC C C T AGAAAGAT AAT CAT AT TGTGACGTACGT T AAAG ATAATCATGCGTAAAATTGACGCATGTGTTTTATCGGTCTGTATATCGAGGTTTA T T T AT T AAT T T GAAT AGAT AT TAAGTTTTATTATATTTACACT TAG AT AC T AAT A AT AAAT T CAACAAACAAT T TAT T TAT GT T TAT T TAT T TAT T AAAAAAAAACAAAA ACTCAAAATTTCTTCTATAAAGTAACAAAACTTTTATCGAATTCCTGCAGCCCGG GGGATCCACTAGTTCTAGAGGGACAGCCCCCCCCCAAAGCCCCCAGGGATGTAAT TACGTCCCTCCCCCGCTAGGGGGCAGCAGCGAGCCGCCCGGGGCTCCGCTCCGGT CCGGCGCTCCCCCCGCATCCCCGAGCCGGCAGCGTGCGGGGACAGCCCGGGCACG GGGAAGGTGGCACGGGATCGCTTTCCTCTGAACGCTTCTCGCTGCTCTTTGAGCC TGCAGACACCTGGGGGGATACGGGGAAAAGGCCTCCAAGGCCAGCTTCCCACAAT AAGTTGGGTGAATTTTGGCTCATTCCTCCTTTCTATAGGATTGAGGTCAGAGCTT TGTGATGGGAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCGCGAT CGCTAGCTTAAGCGCTGATCAATTGGCGCGCCGAATTCGTTGTCTAAGAAACCAT TATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTGATGGCTC TTTGCGGCACCCATCGTTCGTAATGTTCCGTGGCACCGAGGACAACCCTCAAGAG AAAATGTAATCACACTGGCTCACCTTCGGGTGGGCCTTTCTGCGTTTATAAGGAG ACACTTTATGTTTAAGAAGGTTGGTAAATTCCTTGCGGCTTTGGCAGCCAAGCTA GATCCGCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCAC AAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACC AGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCT TACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGC TCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTG TGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCT TGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGC CTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCC AGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCT GGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGAT CTCAAGAAGATCCTTTGATCTCCACCATGGCCACCTCAGCAAGTTCCCACTTGAA CAAAAACATCAAGCAAATGTACTTGTGCCTGCCCCAGGGTGAGAAAGTCCAAGCC ATGTATATCTGGGTTGATGGTACTGGAGAAGGACTGCGCTGCAAAACCCGCACCC TGGACTGTGAGCCCAAGTGTGTAGAAGAGTTACCTGAGTGGAATTTTGATGGCTC TAGTACCTTTCAGTCTGAGGGCTCCAACAGTGACATGTATCTCAGCCCTGTTGCC ATGTTTCGGGACCCCTTCCGCAGAGATCCCAACAAGCTGGTGTTCTGTGAAGTTT TCAAGTACAACCGGAAGCCTGCAGAGACCAATTTAAGGCACTCGTGTAAACGGAT AATGGACATGGTGAGCAACCAGCACCCCTGGTTTGGAATGGAACAGGAGTATACT CTGATGGGAACAGATGGGCACCCTTTTGGTTGGCCTTCCAATGGCTTTCCTGGGCCCCAAGGTCCGTATTACTGTGGTGTGGGCGCAGACAAAGCCTATGGCAGGGATATAttorney Docket No. 0132-0386W01CGTGGAGGCTCACTACCGCGCCTGCTTGTATGCTGGGGTCAAGATTACAGGAACA AATGCTGAGGTCATGCCTGCCCAGTGGGAGTTCCAAATAGGACCCTGTGAAGGAA TCCGCATGGGAGATCATCTCTGGGTGGCCCGTTTCATCTTGCATCGAGTATGTGA AGACTTTGGGGTAATAGCAACCTTTGACCCCAAGCCCATTCCTGGGAACTGGAAT GGTGCAGGCTGCCATACCAACTTTAGCACCAAGGCCATGCGGGAGGAGAATGGTC TGAAGCACATCGAGGAGGCCATCGAGAAACTAAGCAAGCGGCACCGGTACCACAT TCGAGCCTACGATCCCAAGGGGGGCCTGGACAATGCCCGTCGTCTGACTGGGTTC CACGAAACGTCCAACATCAACGACTTTTCTGCTGGTGTCGCCAATCGCAGTGCCA GCATCCGCATTCCCCGGACTGTCGGCCAGGAGAAGAAAGGTTACTTTGAAGACCG CCGCCCCTCTGCCAATTGTGACCCCTTTGCAGTGACAGAAGCCATCGTCCGCACA TGCCTTCTCAATGAGACTGGCGACGAGCCCTTCCAATACAAAAACTAATTAGACT TTGAGTGATCTTGAGCCTTTCCTAGTTCATCCCACCCCGCCCCAGAGAGATCTTT GTGAAGGAACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGA TTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACT GATTCTAATTGTTTGTGTATTTTAGATTCCAACCTATGGAACTGATGAATGGGAG CAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCAT CTAGT GAT GAT GAGGCTACT GCT GACT CT CAACATT CTACT CCT CCAAAAAAGAA GAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGT CATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAAAGG AAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTAACCTTTAT AAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTACTCCACACAGG CATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAGCTTTT TAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGA TCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCC ACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTG TTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAA ATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGT ATCTTATCATGTCTGGATCATCACGCGTTACATAACTTACGGTAAATGGCCCGCC TGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCC ATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGT AAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTAT TGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGG TGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGG ATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGCGTGAGGCTC CGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGG GGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGG AAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTA TATAAGTGCAGTAGTCGCCGTGAACGTTTCGCAGTCTTCGGTCTGACCACCGTAG AACGCAGCCTCAGGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGC CGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACCG CCTATAGAGTCTATAGGCCCACCCCCTTGGCTTCTTATGCATGCTATACTGTTTT TGGCTTGGGGTCTATACACCCCCGCTTCCTCATGTTATAGGTGATGGTATAGCTT AGCCTATAGGTGTGGGTTATTGACCATTATTGACCACTCCCCTATTGGTGACGAT ACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAACTCTCTTTATTGGCT ATATGCCAATACACTGTCCTTCAGAGACTGACACGGACTCTGTATTTTTACAGGA TGGGGTCT CAT T TAT TAT T T AC AAAT T C AC AT AT AC AAC AC CACCGTCCCCAGTG CCCGCAGTTTTTATTAAACATAACGTGGGATCTCCACGCGAATCTCGGGTACGTG TTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCTACATCCGAGCCCTGC TCCCATGCCTCCAGCGACTCATGGTCGCTCGGCAGCTCCTTGCTCCTAACAGTGG AGGCCAGACTTAGGCACAGCACGATGCCCACCACCACCAGTGTGCCGCACAAGGC CGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGGGAGCGGGCTTGCACCGCT GACGCATTTGGAAGACTTAAGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGTTG TTGTGTTCTGATAAGAGTGAAACAAGACAGTTCCGGGCTGGAACAGAGGTAACTC CCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGC TGCCGCGCGCGCCACCAGACATAATAGCTGACAGACTAACAGACTGTTCCTTTCC ATGGGTCTTTTCTGCAGTCACCGTCCTTGACACGAAGCTTGCCGCCACCATGGAA TGGTCCTGGGTGTTCCTGTTCTTCCTGTCCGTGACCACCGGCGTGCACTCTGAGG TGCAGCTGGTCGAGTCTGGGGGAGGACTGGTGCAGCCTGGAGGCTCCCTGAGACT GTCTTGCGCCGCCTCCGGCTTCAACATCAAGGACACCTACATCCACTGGGTCCGCCAGGCTCCAGGCAAGGGACTGGAATGGGTGGCCCGGATCTACCCTACCAACGGCTAttorney Docket No. 0132-0386W01ACACCAGATACGCCGACTCCGTGAAGGGCCGGTTCACCATCTCCGCCGACACCTC CAAGAACACCGCCTATCTGCAGATGAACTCCCTGAGGGCCGAGGACACCGCCGTG TACTACTGCTCCAGATGGGGAGGCGACGGCTTCTACGCCATGGACTACTGGGGCC AGGGCACCCTGGTGACCGTGTCCTCCGCCTCCACCAAGGGCCCTTCCGTGTTCCC TCTGGCCCCTTCCTCCAAGTCTACCTCTGGCGGCACCGCTGCTCTGGGCTGCCTG GTGAAGGACTACTTCCCTGAGCCTGTGACAGTGTCCTGGAACTCTGGCGCCCTGA CCTCTGGAGTGCATACCTTCCCTGCCGTGCTGCAGTCCTCCGGCCTGTACTCCCT GTCCTCCGTGGTGACAGTGCCTTCCTCCTCCCTGGGCACCCAGACCTACATCTGC AACGTGAACCACAAGCCTTCCAACACCAAGGTGGACAAGAAGGTGGAGCCTAAGT CCTGCGACAAGACCCACACCTGTCCTCCATGCCCTGCCCCTGAGCTGCTGGGCGG ACCTTCTGTGTTTCTGTTCCCTCCTAAGCCTAAGGACACCCTGATGATCTCCCGG ACCCCTGAAGTGACCTGTGTGGTGGTGGACGTGTCCCACGAGGATCCTGAAGTGA AGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCTAG AGAGGAACAGTACAACTCCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCAC CAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGCCCTGC CTGCCCCTATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTCGGGAACCTCA GGTGTACACCCTGCCTCCATCTCGGGAGGAAATGACCAAGAACCAGGTGTCCCTG ACCTGTCTGGTGAAGGGCTTCTACCCTTCCGATATCGCCGTGGAGTGGGAGTCTA ACGGCCAGCCTGAGAACAACTACAAGACCACCCCTCCTGTGCTGGACTCCGACGG CTCCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAGGGC AACGTGTTCTCCTGCTCTGTGATGCACGAGGCCCTGCACAACCACTACACCCAGA AGTCCCTGTCCCTGTCTCCTGGCAAGTGATGAGAATTCATTGATCATAATCAGCC ATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCT GAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCT T AT AAT G GT T AC AAAT AAAG C AAT AG CAT C AC AAAT T T C AC AAAT AAAG CAT T T T TTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGT CTGGGTACAGCAGGACTATGAAACCGGTTCGACGCGTTACATAACTTACGGTAAA TGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACG TATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC GCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTAC ATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTA TTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGA CTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGC GTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAG AAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGG TAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGG AGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTTCGCAGTCTTCGGTCTGA CCACCGTAGAACGCAGCCTCAGGACCTCCATAGAAGACACCGGGACCGATCCAGC CTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACG TAAGTACCGCCTATAGAGTCTATAGGCCCACCCCCTTGGCTTCTTATGCATGCTA TACTGTTTTTGGCTTGGGGTCTATACACCCCCGCTTCCTCATGTTATAGGTGATG GTATAGCTTAGCCTATAGGTGTGGGTTATTGACCATTATTGACCACTCCCCTATT GGTGACGATACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAACTCTCT TTATTGGCTATATGCCAATACACTGTCCTTCAGAGACTGACACGGACTCTGTATT TTTACAGGATGGGGTCTCATTTATTATTTACAAATTCACATATACAACACCACCG TCCCCAGTGCCCGCAGTTTTTATTAAACATAACGTGGGATCTCCACGCGAATCTC GGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCTACATCC GAGCCCTGCTCCCATGCCTCCAGCGACTCATGGTCGCTCGGCAGCTCCTTGCTCC TAACAGTGGAGGCCAGACTTAGGCACAGCACGATGCCCACCACCACCAGTGTGCC GCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGGGAGCGGGCT TGCACCGCTGACGCATTTGGAAGACTTAAGGCAGCGGCAGAAGAAGATGCAGGCA GCTGAGTTGTTGTGTTCTGATAAGAGTACAAAGGCAACATCCTCACTTGGGTCAG AGGTAACTCCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGT ACTCGTTGCTGCCGCGCGCGCCACCAGACATAATAGCTGACAGACTAACAGACTG TTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCCTTGACACGAAGCTTGCCGCC ACCATGTCCGTGCCTACCCAGGTGCTGGGACTGCTGCTGCTGTGGCTGACCGACG CCAGATGCGACATCCAGATGACCCAGTCCCCCTCCTCCCTGTCTGCCTCCGTGGG CGACAGAGTGACCATCACCTGTCGGGCCTCCCAGGATGTGAACACCGCCGTGGCC TGGTATCAGCAGAAGCCTGGCAAGGCCCCTAAGCTGCTGATCTACTCCGCCTCCTTCCTGTACTCCGGCGTGCCTTCCCGGTTCTCCGGCTCCAGATCCGGCACCGACTTAttorney Docket No. 0132-0386W01CACCCTGACCATCTCCAGCCTGCAGCCTGAGGACTTCGCCACCTACTACTGCCAG CAGCACTACACCACCCCTCCAACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGC GGACCGTGGCCGCTCCTTCCGTGTTCATCTTCCCTCCCTCCGACGAGCAGCTGAA GTCCGGCACCGCCTCTGTCGTGTGCCTGCTGAACAACTTCTACCCTCGGGAGGCC AAGGTGCAGTGGAAGGTGGACAACGCCCTGCAGTCCGGCAACTCCCAGGAATCCG TCACCGAGCAGGACTCCAAGGACTCTACCTACTCCCTGTCCTCCACCCTGACCCT GTCCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAG GGCCTGTCCTCTCCCGTGACCAAGTCCTTCAACCGGGGCGAGTGCTGATGAATTC ATTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAAC CTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTA ACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTT CACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGAACCGAAACGCGGTATCAAGGTTAEXAMPLESExample 1: Enhanced GS selection in pools through novel vector design and new fusion promoter.
[0088] The expression vectors described in embodiments herein were inserted into GS piggyBac® antibody expression vectors for comparison of selection pool recovery and POI production in CHOK1SV GS-KO cells. The vectors used in the following experiments comprise either a conventional mCMV promoter or hEFla-hCMV promoter operably linked to the GOI. The hEFla-hCMV promoter comprises 407 nucleotides of the hCMV enhancer sequence and 203 nucleotides of the hEFla promoter. The vectors comprising the mCMV or hEFla-hCMV promoter driving GOI expression may also comprise either SV40E, A2SV40E (Fan et al., J Biotechnol. 168(4):652-658 (2013)), or Ori operably linked to the glutamine synthetase (GS) gene.
[0089] General Protocol: stable pool testing
[0090] Stably expressing CHOK1 SV GS-KO pools were generated by transfecting cells with 40 pg of GS piggyBac® plasmid DNA and 4 pg of piggyBac transposase mRNA using BioRad® Gene Pulser Xcell. Electroporated cells were resuspended in 10 mL protein-free medium containing 1% HT in TPP TubeSpin® Bioreactor 50. At 24 h post-transfection, transfected cells were centrifuged at 200*g for 5 min and cell pellets were resuspended in 10 mL protein-free medium containing 1% HT and varying concentrations of MSX (0-50 pM) to select for stable transfectants. MSX was applied during stable pool generation, which was then withdrawn prior to fed-batch cultures as further described below. The stably transfected pools were cryopreserved in protein-free medium containing 7.5% DMSO when the viability of pools recovered above 97%. Cell viability and viable cell concentration were measured using Vi-CELL® XR. Production of each stably transfected pool was determined in Ambr®15 fed-batch cultures. Cells were seeded at 0.5*106cells / mL and cultured for 15 daysAttorney Docket No. 0132-0386W01at 36.5°C with a shift to 33°C at Day 7. Recombinant mAb concentration in cell culture supernatant was measured using PrA HPLC.
[0091] CHOK1SV GS-KO cells were electroporated with GS piggyBac® vectors as described above expressing a monospecific antibody, mAbl. Stable pool recovery of the CHOK1SV GS-KO cells was tested. Viable cell concentration (VCC) (FIG. 2A and 2B) and cell viability (FIG. 2C and 2D) and were measured at day 5 post-transfection. Results are shown in FIGS. 2A-2D («=3). Cells expressing the Ori-hEFla-hCMV GS vector with no MSX treatment demonstrated comparable VCC and cell viability at 5 days post-transfection as those expressing the conventional SV40E-mCMV vector with MSX.
[0092] Further, the POI expression levels for the stable CHOK1SV GS-KO pools expressing mAbl from the expression vectors described above were compared. The average fed-batch culture titer and the glutamine concentration in the cell culture media at day 10 of fed-batch culture was determined. Results of mAbl titers are shown in FIG. 3 A and 3B and glutamine concentration is shown in FIG. 3C and 3D (ft=3). Cells expressing the Ori-hEFla-hCMV GS vector with little to no MSX treatment demonstrated similar or higher mAb 1 titers than those expressing the conventional SV40E-mCMV vector. Additionally, cells expressing the Ori-hEFla-hCMV GS vector with little to no MSX treatment demonstrated similar or lower glutamine concentration than those expressing the conventional SV40E-mCMV vector, demonstrating increased selection stringency.
[0093] Further, the expression levels for the stable CHOK1SV GS-KO pools expressing a different monospecific antibody (mAb2) or a bispecific antibody (bsAbl) from the expression vectors described above were compared. 0-50 pM MSX was applied during stable pool generation, which was then withdrawn prior to fed-batch cultures. The average fed-batch culture titer and the glutamine concentration in the cell culture media at day 10 of fed-batch culture was determined. Results of mAb2 and bsAbl titers are shown in FIG. 4A and 4B and the corresponding glutamine concentrations are shown in FIG. 4C and 4D (ft=3). Cells expressing the Ori-hEFla-hCMV GS vector with little to no MSX treatment demonstrated similar or higher mAb2 and bsAbl titers than those expressing the conventional SV40E-mCMV vector. Additionally, cells expressing the Ori-hEFla-hCMV GS vector with little to no MSX treatment demonstrated lower glutamine concentration than those expressing the conventional SV40E-mCMV vector.
[0094] The expression vectors described above can be modified to include up to 1 lx repeat copies of an AU-rich element operably linked to the glutamine synthetase gene, as shown inAttorney Docket No. 0132-0386W01FIG. 1C. Similar to the previous experiments, 0-50 pM MSX was applied during stable pool generation, which was then withdrawn prior to fed-batch cultures. The average fed-batch culture titer of pools generated using an expression vector with 7x repeat copies of an AU-rich element is shown in FIG. 5A and 5B («=3). Cells expressing the Ori- hEFla-hCMV-AU-rich GS vector with no MSX treatment demonstrated similar mAbl titers to those expressing the conventional SV40E-mCMV vector or the SV40E-mCMV-AU-rich vector.
[0095] The bulk-pool stability of antibody expression over 30 days for the stable CHOK1SV GS-KO pools expressing a monospecific antibody (mAbl, mAb2, mAb3, or mAb4) or a bispecific antibody (bsAbl, bsAb2, bsAb3, or bsAb4) from the expression vectors described above were compared («=3). Stable pools of cells with the SV40-mCMV, SV40-hEFla-hCMV, and Ori-hEFla-hCMV vectors were generated as described herein. For the SV40 promoters, 50 pM MSX was applied during stable pool generation, which was then withdrawn prior to long-term culture and fed-batch process. The fed-batch culture titer of mAbl was measured at day 0 and day 30 of culture and the expression of mAbl was compared as shown in FIG. 6A. Pools harboring the Ori-hEFla-hCMV GS vector (generated with 0 pM MSX) exhibited highly stable long-term expression stability (< 15% change in titer after 30 days in culture) compared to the conventional SV40-mCMV GS vector (generated with 50 pM MSX). The bulk pool stability of mAb2, mAb3, mAb4, bsAbl, bsAb2, bsAb3, and bsAb4 titer in cells with the Ori-hEFla-hCMV vector was also measured over 30 days in culture, as shown in FIGS. 6B to 6H. All mAb2, mAb3, mAb4, bsAbl, bsAb2, bsAb3, and bsAb4 exhibited stable titers over 30 days in culture.
[0096] The glycosylation profiles of mAbl, mAb2, mAb4, bsAbl, bsAb2, and bsAb3 produced from the SV40-hEFla-hCMV and Ori-hEFla-hCMV vectors described above were determined. The samples were prepared using Gly-X in accordance with standard procedures, and the glycan profiles of the prepared samples were subsequently analyzed by ultraperformance liquid chromatography (UPLC). The results are shown in FIGS. 7A to 7F.Similar glycosylation profiles of the antibodies produced from either vector were observed.
[0097] Monomer and aggregate levels of mAbl, mAb2, mAb3, mAb4, bsAbl, bsAb2, and bsAb3 produced from the SV40-hEFla-hCMV and Ori-hEFla-hCMV vectors described above were evaluated using gel-permeation chromatography (GPC). The results are shown in FIGS. 8A-8G. Comparable monomer levels for each antibody were produced by either vector.Attorney Docket No. 0132-0386W01
[0098] Chain pairing, expressed as the percentage of correctly assembled bispecific antibodies (bsAbl, bsAb2, bsAb3, bsAb4) produced from the SV40-hEFla-hCMV and Ori-hEFla-hCMV vectors described above, was determined using native liquid chromatographymass spectrometry (LC-MS). The results are shown in FIGS. 9A-9D. Comparable chain pairing levels were observed for each antibody produced from either vector.
[0099] The relative cell-specific productivity (rQp) as measured by the BEACON® Optofluidic system for clones derived from pools generated using hEFla-hCMV GS vectors. A total of 2,220 clones from pools produced from the SV40-hEFla-hCMV vector ("SV40 pools") and 2,036 clones from pools produced from the Ori-hEFla-hCMV vector ("Ori pools") were selected based on confirmation of single-cell origin and the presence of at least six cells on Day 4 post-loading onto the BEACON® instrument. For the SV40 pools, 50 pM MSX was applied during stable pool generation, which was then withdrawn during cloning. The results are shown in FIG. 10 A. The fed-batch titers of the top 22 clones for each vector are shown in FIG. 10B. The two pools from which the top 22 clones were derived are shown in FIG. 10B as open bars.
[0100] Similarly, clones derived from mAb3 -expressing pools were generated using the conventional SV40E-mCMV vector, SV40-hEFla-hCMV vector, or the Ori-hEFla-hCMV vector. For those with SV40 promoters, 50 pM MSX was applied during stable pool generation, which was then withdrawn during cloning. The fed-batch titers of the top clones for each vector are shown in FIG. 11.
Claims
Attorney Docket No. 0132-0386W01CLAIMSWhat is claimed is:
1. An expression vector comprising:a. a bacterial origin of replication (Ori) comprising a cryptic TATA box and / or a cryptic transcription start site, the Ori operably linked to a glutamine synthetase gene; andb. a transcription control element comprising:i. an enhancer nucleotide sequence comprising about 300 to about 410 nucleotides of a human cytomegalovirus (hCMV) sequence; and ii. a mammalian endogenous promoter,wherein the transcription control element is operably linked to a gene of interest (GOI).
2. The expression vector of claim 1, wherein the transcription control element provides increased control of expression of the glutamine synthetase gene.
3. The expression vector of claims 1 or 2, wherein the transcription control element comprises the enhancer nucleotide sequence comprising about 400 to about 410 nucleotides of the human cytomegalovirus (hCMV) sequence and a human EFla promoter.
4. The expression vector of any one of claims 1-3, wherein the Ori comprises any one of SEQ ID NO: 17-22.
5. The expression vector of any one of claims 1-4, wherein the transcription control element comprises an enhancer nucleotide sequence of any one of SEQ ID NO: 7-9.
6. The expression vector of any one of claims 1-5, wherein the transcription control element comprises a mammalian endogenous promoter of any one of SEQ ID NO: 1- 6.
7. The expression vector of any one of claims 1-6, wherein the transcription control element comprises any one of SEQ ID NO: 10-16.
8. The expression vector of any one of claims 1-7, further comprising an AU-richelement.Attorney Docket No. 0132-0386W019. The expression vector of claim 8, wherein the AU-rich element comprises SEQ ID NO: 26.
10. The expression vector of claims 8 or 9, wherein the expression vector comprises 1 to 11 copies of the AU-rich element.
11. The expression vector of any one of claims 1-10, further comprising a selectable marker for bacterial expression.
12. The expression vector of claim 11, wherein the selectable marker is an ampicillin resistance gene, a kanamycin resistance gene, a chloramphenicol resistance gene, or tetracycline resistance gene, or combinations thereof.
13. The expression vector of any one of claims 1-12, wherein the GOI encodes a polypeptide of interest.
14. The expression vector of claim 13, wherein the polypeptide of interest is an antibody or antigen-binding fragment thereof, a fusion protein, an immunoglobulin, an engineered protein, a protein fragment or an enzyme.
15. The expression vector of claims 13 or 14, wherein the polypeptide of interest is monospecific antibody, a bispecific antibody, or a multi-specific antibody, or antigenbinding fragments thereof.
16. The expression vector of any one of claims 1-15, wherein the vector comprises about 345 fewer nucleotides and / or one fewer genetic element as compared to an expression vector in which an Ori is not operably linked to a glutamine synthetase gene.
17. A stably integrated cell comprising the expression vector of any one of claims 1-16.
18. The cell of claim 17, wherein the cell is a mammalian cell.
19. The cell of claims 17 or 18, wherein the cell is a CHO cell or CHO-derived cell.
20. The cell of claim 19, wherein the CHO cell is CHOK1SV.
21. The cell of any one of claims 18-20, wherein the CHO cell comprises a deletion of an endogenous glutamine synthetase gene.
22. A method of expressing a polypeptide of interest in a host cell comprising culturing the stability integrated cell of any one of claims 17-21 under suitable conditions to produce a polypeptide of interest.Attorney Docket No. 0132-0386W0123. The method of claim 22, wherein the method produces less than about 15% change in titer of a stable pool after 30 days in culture as compared to a method utilizing an expression vector in which an Ori is not operably linked to a glutamine synthetase gene.
24. A method of selecting a cell expressing a gene of interest (GOI), comprising:a. transfecting into a cell that lacks glutamine synthetase, an expression vector comprising:i. a bacterial origin of replication (Ori) comprising a cryptic TATA box and / or a cryptic transcription start site, the Ori operably linked to a glutamine synthetase gene; andii. a transcription control element comprising:
1. an enhancer nucleotide sequence comprising about 400 to about 410 nucleotides of a human cytomegalovirus (hCMV) sequence; and2. a mammalian endogenous promoter,wherein the transcription control element is operably linked to a gene of interest (GOI) encoding a polypeptide of interest (POI); and b. culturing the transfected cells under conditions that select for cells which stably integrate the vector.
25. The method of claim 24, wherein the method provides increased control of expression of the glutamine synthetase gene as compared to a method utilizing an expression vector comprising a viral promoter instead of the transcriptional control element.
26. The method of claims 24 or 25, wherein the mammalian endogenous promoter is the hEF 1 a promoter.
27. The method of any one of claims 24-26, wherein the cells which stably integrate the vector are selected by culturing the transfected cells without glutamine.
28. The method of any one of claims 24-27, wherein methionine sulfoximine (MSX) is not used in the culturing of the transfected cells.
29. The method of claim any one of claims 24-28, wherein the transfected cells are mammalian cells.Attorney Docket No. 0132-0386W0130. The method of any one of claims 24-29, wherein the transfected cells are CHO cells or CHO-derived cells.
31. The method of any one of claims 24-30, wherein the transfected cells are CHOK1 SV cells.
32. The method of any one of claims 30-31, wherein the CHO cells comprise a deletion of an endogenous glutamine synthetase gene.
33. The method of any one of claims 24-32, wherein the GOI encodes a polypeptide of interest.
34. The method of claim 33, wherein the polypeptide of interest is an antibody, or antigen-binding fragment thereof, a fusion protein, an immunoglobulin, an engineered protein, a protein fragment or an enzyme.
35. The method of claim 33 or claim 34, wherein the polypeptide of interest is monospecific antibody, a bispecific antibody, or a multi-specific antibody, or antigenbinding fragments thereof.
36. A method of producing a polypeptide of interest in a host cell comprising selecting cells with the method from any one of claims 24-35 and isolating the POI.
37. The method of any one of claims 24-36, wherein the method less than about 15% change in titer of a stable pool after 30 days in culture as compared to a method utilizing an expression vector in which an Ori is not operably linked to a glutamine synthetase gene.
38. The method of any one of claims 24-37, wherein the expression vector comprises about 345 fewer nucleotides and / or one fewer genetic element as compared to an expression vector in which an Ori is not operably linked to a glutamine synthetase gene.
